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AbstrAct
Objective When faced with clinical symptoms of scarring 
alopecia—the standard diagnostic pathway involves a 
scalp biopsy which is an invasive and expensive procedure. 
This project aimed to assess if plucked hair follicles (HFs) 
containing living epithelial cells can offer a non-invasive 
approach to diagnosing inflammatory scalp lesions.
Methods Lesional and non-lesional HFs were extracted 
from the scalp of patients with chronic discoid lupus 
erythematosus (CDLE), psoriasis and healthy controls. RNA 
was isolated from plucked anagen HFs and microarray, as 
well as quantitative real-time PCR was performed.
Results Here, we report that gene expression analysis of 
only a small number of HF plucked from lesional areas of 
the scalp is sufficient to differentiate CDLE from psoriasis 
lesions or healthy HF. The expression profile from CDLE 
HFs coincides with published profiles of CDLE from skin 
biopsy. Genes that were highly expressed in lesional 
CDLE corresponded to well-known histopathological 
diagnostic features of CDLE and included those related to 
apoptotic cell death, the interferon signature, complement 
components and CD8+ T-cell immune responses.
Conclusions We therefore propose that information 
obtained from this non-invasive approach are sufficient 
to diagnose scalp lupus erythematosus. Once validated in 
routine clinical settings and compared with other scarring 
alopecias, this rapid and non-invasive approach will have 
great potential for paving the way for future diagnosis of 
inflammatory scalp lesions.
IntROduCtIOn
Cutaneous lupus erythematosus (CLE) can 
present as part of the SLE spectrum or as a 
‘skin only’ disease.1 Up to 80% of all CLE 
cases seen in dermatology settings are diag-
nosed to be chronic discoid lupus erythema-
tosus (CDLE).2 In most patients with CDLE, 
lesions are predominantly in sun-exposed 
areas including face, neck, décolletage and, 
importantly, the scalp with often disfiguring 
lesions resulting in permanent scarring and 
irreversible hair loss.3–5 CLE in visible parts 
of the body is well recognised to significantly 
affect the quality of life of patients.6
Although CDLE can be diagnosed by expe-
rienced dermatologists based on morpho-
logical characteristics including erythema, 
pigmentary disturbances, telangiectasia and 
atrophy, a skin biopsy is usually required to 
confirm the diagnosis. Histopathological 
and immunohistological findings include 
interface dermatitis7 with a dense, predom-
inantly CD8+ T-cell lymphocytic infiltrate 
particularly around the bulge region of 
the hair follicle (HF), basal cell/vacuolar 
degeneration representing apoptotic kera-
tinocytes, basement membrane changes, 
infiltrating macrophages and plasmacytoid 
dendritic cells, pilosebaceous destruction 
and atrophic scarring.4 8–10 Many of these 
features are also seen in lichen planopilaris 
(LPP), a chronic inflammatory skin disease 
which also leads to permanent scarring 
alopecia.11–14 However, deposition of immu-
noglobulins and complement component 3 
(C3) at the dermoepidermal junction as seen 
using direct immunofluorescence (DIF) is 
specific for CDLE but not LPP and thus a key 
differential diagnostic finding. Performing a 
scalp biopsy for histology and DIF is an inva-
sive, thus often stressful procedure for the 
patient. It also requires availability of trained 
doctors and nurses, a special biopsy set-up 
with sterile equipment, patient’s consent 
regarding the side effects of local anaesthetic 
and invasive biopsy (including infection, scar, 
healing problems and bleeding) and usually 
a separate appointment, thus further time 
commitment for the patient. Furthermore, 
the biopsy needs to be processed, analysed 
and communicated by a dermatohistopa-
thologist which takes up to 4 weeks in a stan-
dard dermatology setting. Thus, the overall 
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costs involved to receive a conventional biopsy histology 
report are several hundred pounds/Euro (depending on 
the health system used).
A molecular hallmark of lupus erythematosus lesions 
is the high expression of interferon (IFN)-stimulated 
genes (ISGs).9 15 16 These include myxovirus protein A 
(MxA),17 IFN inducible protein 6 (IFI6), CXCL9, CXCL10, 
2,5-oligoadenylate synthase (OAS) including OAS2 
and OASL, IFN-induced helicase C domain-containing 
protein 1 (IFIH1/MDA5), bone marrow stromal antigen 
2 (BST2) and guanylate-binding protein 1 (GBP1) in CLE 
lesions.8 18–21 It is well known that IFNs induce expression 
of major histocompatibility complex (MHC) class I and 
MHC class I-pathway related molecules (β2 microglob-
ulin, β2M) and this has also been reported for organ-cul-
tured human scalp skin.22–24 The proposed mechanism 
responsible for high expression of ISG includes the 
impaired clearance of apoptotic material, which results 
in secondary necrosis and release of immunostimulatory 
nucleic acids.25–27 An upregulated IFN response goes 
along with antiproliferative and antineovascularisation 
properties and may be involved in the downregulation 
of tissue repair mechanisms observed in CDLE.9 25 28 
However, psoriasis which often presents with strong scalp 
involvement but never resulting in scars is also recognised 
to have some activation of the IFN pathway.29 In this work, 
we aimed to explore the potential of plucked HF anal-
ysis to identify CDLE-specific changes. We mainly focused 
on differentially expressed genes comparing HFs from 
lesional versus non-lesional areas of the scalp. Psoriasis 
samples were also included in our analysis, as a disease 
comparator which shows significant scalp inflammation 
with leukocyte infiltration but presents with different clin-
ical outcomes regarding atrophy and scarring.30
MateRIals and MethOds
Patients
All patients had confirmed psoriasis as diagnosed by 
consultant dermatologists or CDLE (biopsy proven) and 
had been suffering long term (eg, longer than 5 years). 
All patients showed clinically active scalp lesions. Most 
patients with CDLE were on hydroxychloroquine but 
were asked to discontinue the drug for 3–5 days prior 
sampling. All patients with CDLE were female (age range 
20–75 years of age, mean 55), 80% of healthy controls were 
female (mean age 46) and for patients with psoriasis, 50% 
were male and 50% female (mean age 43 years). Patients 
had not used topical corticosteroids within 48 hours prior 
to sampling. All individuals provided informed written 
consent and this research was carried out in compliance 
with the Declaration of Helsinki. The patients’ samples 
used for this study were collected under ethical approval, 
REC 10/H1306/88, National Research Ethics Committee 
Yorkshire and Humber–Leeds East. All experiments were 
performed in accordance with relevant guidelines and 
regulations.
Plucked hF samples
Four to five HFs from five healthy individuals (male and 
female aged 35–55 years), seven patients with CDLE from 
both lesional and non-lesional areas and six patients with 
psoriasis from both lesional and non-lesional areas were 
plucked out using tweezers as described previously.31 Only 
hairs with a full, visible HF were used (eg, telogen hairs or 
those with incompletely plucked follicle were excluded). 
Time to pluck four to five anagen hairs with suitable HFs 
usually takes an experienced person 5 min as up to 10 
hairs have to be plucked to obtain this yield. In this study, 
we have restricted the area of ‘lesional’ sampling to scalp 
presenting with clinical signs of inflammation, such as 
erythema (including mild erythema), infiltration, hyper-
keratosis/scaling. The hair shaft was cut-off and the white 
sheath (inner and outer root sheath) containing kerati-
nocytes were used for this study (figure 3). Trimmed HFs 
were then immersed in Optimal Cutting Temperature 
(OCT) compound (Tissue-Tek; Sakura Finetek Europe, 
Alphen aan den Rijn, The Netherlands) in 1.5 mL tubes 
to preserve RNA quality before further processing. The 
samples were either stored in −80°C or processed imme-
diately for RNA extraction.
total Rna extraction from hFs
Plucked HFs were embedded longitudinally in OCT 
and 3–5 µm thick frozen sections were cut using a Leica 
CM3050S cryostat (Leica Microsystems, Buckingham-
shire, UK) and collected in RNase free universal tubes. 
This was followed by the addition of lysis buffer (Relia-
Prep RNA Cell Miniprep System; Promega, Wisconsin, 
USA) to the cut HF sections which were stored on dry 
ice prior to RNA extraction, which was carried out 
according to the manufacturer’s protocol. The quantity 
of the extracted RNA was measured using a NanoDrop 
2000 (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA), and the RNA quality was checked by an Agilent 
tape station Bioanalyser. RNA integrity number (RIN) 
number for RNA samples typically ranged between 7.5 
and 10, with the majority of samples between 9 and 10, 
as determined at the Genomic Core Facility (GeneCore) 
in the European Molecular Biology Laboratory (EMBL, 
Heidelberg, Germany).
transcriptomic and gene microarray analyses
At least 100 ng of the extracted total RNA was used 
as an input for microarray analysis done for each indi-
vidual. Samples were processed at the EMBL GeneCore 
Facility for Affymetrix Microarray analysis (Geo number 
GSE119207). Gene Spring analysis was performed; in 
addition, Affymetrix CHP data were analysed with Tran-
scriptome Analysis Console 3.1 software using HuGene-
2_0-st-v1 library file from Affymetrix. A cut-off level of 
1.5-fold change in the expression was used to analyse the 
differential gene expression when comparing lesional, 
non-lesional and healthy conditions. A selection of target 
genes identified by microarray was then validated via 
quantitative real-time PCR (qRT-PCR).
 o
n
 19 July 2019 by guest. Protected by copyright.
http://lupus.bmj.com/
Lupus Sci M
ed: first published as 10.1136/lupus-2019-000328 on 14 July 2019. Downloaded from
 
Shalbaf M, et al. Lupus Science & Medicine 2019;6:e000328. doi:10.1136/lupus-2019-000328 3
Cutaneous lupus
Figure 3 Proposed pathogenically relevant genes overexpressed in lesional CDLE HF. Photographs show HF plucked from 
the scalp area and used for RNA extraction. A longitudinal HF section is shown in H&E stain highlighting outer root, inner root 
sheath and hair bulb. The green box shows differentially expressed genes in lesional CDLE HF samples versus non-lesional/
healthy control samples. Dermatohistopathology features (right-hand pictures, CDLE biopsies from routine diagnosis, pictures 
provided by dermatohistopathology, Leeds) such as vacuolar degeneration (apoptosis–XAF1), lupus band (middle picture direct 
immunofluorescence; deposition of immunoglobulin and complement–C3), CD8+ T-cell immune responses (β2M, CXCL9), 
atrophy (BMP2) along with IFN-stimulated genes (MxA, IFI6, IFIH1) correspond to highlighted genes in lesional CDLE HFs. β2M, 
β2 microglobulin; BMP2, bone morphogenetic protein 2; CDLE, chronic discoid lupus erythematosus; HF, hair follicle; IFI6, IFN 
inducible protein 6; IFN, interferon; MxA, myxovirus protein A; qRT-PCR, quantitative real-time PCR.
Quantitative real-time PCR
The mRNA expression of the target genes performed 
for each individual sample in this study was determined 
with qRT-PCR using a QuantStudio5 Real-Time PCR 
system (Applied Biosystems, Foster City, California, 
USA) using Qiagen QuantiTect SYBR Green Master 
Mix (Qiagen, Manchester, UK). 50–100 ng of total RNA 
was reverse transcribed using a RevertAid First Strand 
cDNA Synthesis Kit (Thermo Scientific, Loughborough, 
UK) according to the manufacturer’s instructions. MxA, 
IFI6, IFIH1, CXCL9, CXCL10, BST2, OAS2, OASL, XAF1, 
BMP2, β2M, C3 and KDR QuantiTect primer assays were 
purchased from Qiagen (Hilden, Germany), whereas 
U6 snRNA32 primer (forward—5′-CTCGCTTCGGCAG-
CACA-3′ and reverse—5′-AACGCTTCACGAATTTGC-3′) 
was purchased from Sigma (Sigma-Aldrich, Poole, UK). 
The following parameters were used: initial heat acti-
vation, 95°C for 5 min; denaturation, 95°C for 10 s; 
combined annealing and elongation, 60°C for 30 s for a 
40 cycle run. Data were analysed using the ΔΔCT method. 
mRNA expression of each gene of interest was normal-
ised to U6snRNA housekeeping gene.
Statistical analysis of qRT-PCR results were analysed with 
GraphPad Prism software, V.7.00 (GraphPad Software, 
La Jolla, San Diego, California, USA). Results for each 
group are depicted as mean±SEM. Data were analysed by 
using one-way analysis of variance (ANOVA) followed by 
the Tukey multiple comparison test to determine statis-
tically significant differences between groups: *p<0.05, 
**p<0.01.
Results
Microarray analysis of plucked hFs reveals a strong IFn 
signature and differential expression of complement, 
apoptosis and MhC I related genes in Cdle lesions
When comparing matched lesional and non-lesional 
CDLE samples for each patient as well as lesional CDLE 
with healthy samples, analysis of Affymetrix CHP data 
with Transcriptome Analysis Console showed substan-
tial upregulation of ISGs, in particular Mx1, IFI6, BST2, 
OAS2 and CXCL10. This analysis also revealed significant 
upregulation between CDLE lesional samples compared 
with non-lesional or healthy samples of β2M, complement 
factor 3 (C3) and of genes involved in apoptotic cell death 
(XAF1, OAS2) which are also known to be IFN inducible 
(figure 1). Gene Spring analysis of the same microarray 
dataset indicated that the most robustly differentially 
expressed genes (p <0.005) in lesional versus non-le-
sional CDLE included β2M, TLR3, C1R, TAP1, SAMHD1, 
IRF1, XAF1, GBP1, OAS2, C3, IFI27, STAT1, CXCL10 and 
IFIH1/MDA5. Lesional CDLE samples showed the same 
set of genes consistently differentially expressed (p 
<0.005 for β2M, TLR3, C1R, TAP1, SAMHD1, XAF1, GBP1, 
OAS2, C3, IFI27, STAT1 and Mx1), when compared with 
healthy controls (online supplementary tables 1 and 2). 
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Figure 1 Microarray analysis of plucked HF from healthy, lesional and non-lesional CDLE. (A) Hierarchical clustering comparing 
gene expression in HFs between healthy individuals and non-lesional CDLE and (B) between lesional and non-lesional CDLE. 
(C) Fold change of selected genes from microarray analysis comparing lesional with non-lesional CDLE, and (D) lesional CDLE 
with healthy. Genes which were also validated by qRT-PCR are indicated in blue. CXCL9 was not expressed in healthy samples 
and fold change can therefore not be given. CDLE, chronic discoid lupus erythematosus; HF, hair follicle; qRT-PCR, quantitative 
real-time PCR.
Thus, with regard to differentially expressed genes asso-
ciated with lupus pathology, such as ISGs, there is no 
significant overall difference between non-lesional and 
healthy samples as illustrated by the HeatMap overview 
(figure 1A) and figure 1B–D. However, subtle differences 
existed, such as lack of CXCL9 expression in healthy but 
not in non-lesional CDLE. Interestingly, β2M was signifi-
cantly upregulated in non-lesional CDLE (p=3.80×10−4) 
compared with healthy samples in the Gene Spring anal-
ysis.
 o
n
 19 July 2019 by guest. Protected by copyright.
http://lupus.bmj.com/
Lupus Sci M
ed: first published as 10.1136/lupus-2019-000328 on 14 July 2019. Downloaded from
 
Shalbaf M, et al. Lupus Science & Medicine 2019;6:e000328. doi:10.1136/lupus-2019-000328 5
Cutaneous lupus
Figure 2 Differential gene expression in HF from lesional and non-lesional scalp. Selected genes were validated by qRT-
PCR and expression compared between lesional and non-lesional psoriasis, CDLE as well as healthy individuals. Genes 
selected include IFN-stimulated genes (MxA, IFI6, CXCL9, IFIH1), apoptosis-related genes (XAF1), MHC class I antigen 
presentation pathway (β2M), complement factors (C3) and tissue repair-related gene (BMP2). Gene expression was normalised 
to housekeeping gene U6snRNA; arbitrary units are given. Except for BMP2, the same level of significance was also found 
between lesional CDLE and both psoriasis samples (not depicted for reason of clarity). β2M, β2 microglobulin; BMP2, bone 
morphogenetic protein 2; CDLE, chronic discoid lupus erythematosus; HF, hair follicle; IFI6, IFN inducible protein 6; IFN, 
interferon; MHC, major histocompatibility complex; MxA, myxovirus protein A; qRT-PCR, quantitative real-time PCR.
Table 1 presents the fold change differences between 
genes validated by qRT-PCR when comparing average 
expression in lesional CDLE or psoriasis versus healthy 
control samples
Fold difference
Gene symbol
Lesional CDLE 
versus healthy
Lesional psoriasis 
versus healthy
Mx1 266* 2.5
IFI6 156* 1.3
CXCL9 498* 1.7
CXCL10 40* –
BST2 2742 5
IFIH1 8.5* 0.6
OAS2 – –
OASL – –
BMP2 0.09 1.4
XAF1 101* 2.2
β2M 13* 1
C3 12.6* 2.4
KDR 2.8 275
*Indicates genes which were found significantly different using 
multiple comparison analysis. Fold changes for OAS2 and OASL 
cannot be given as no expression was detected in healthy controls.
CDLE, chronic discoid lupus erythematosus; OAS, 
2,5-oligoadenylate synthase; qRT-PCR, quantitative real-time PCR.
PCR analysis confirms that a set of genes related to IFn 
response, complement expression, apoptosis and MhC class I 
presentation characterises Cdle lesions
To confirm findings from the microarray analysis, 
qRT-PCR was performed on the same individual samples 
used in microarray analysis, as well as samples from 
patients with active scalp psoriasis. Expression of ISGs 
(Mx1, IFI6, CXCL9, CXCL10, IFIH1/MDA5), ISGs which 
are also apoptosis-related (XAF1), β2M and C3 were signif-
icantly higher in lesional CDLE as compared with lesional 
psoriasis or healthy samples (figure 2). Consistent with 
microarray data, no significant differences in ISGs expres-
sion between non-lesional CDLE and healthy samples 
were found. Interestingly, bone morphogenetic protein 
2 (BMP2) was found downregulated in both lesional 
and non-lesional CDLE samples compared with psoriasis 
and/or healthy samples. Table 1 provides an overview 
regarding the fold changes of validated genes comparing 
CDLE with healthy samples and psoriasis with the same 
set of healthy samples. We failed to detect a marked 
IFN signature in psoriasis with the exception of slightly 
increased Mx1 and BST2. However, Kinase insert domain 
receptor (KDR) which codes for vascular endothelial 
growth factor receptor 2 (VEGFR2) was markedly upreg-
ulated in psoriatic samples but not significantly regulated 
in CDLE samples.
dIsCussIOn
CDLE manifests with chronic inflammatory skin lesions 
which leads to permanent scarring, resulting in irre-
versible alopecia when affecting the scalp area.5 33 Early 
lesions can be confused with other inflammatory or 
infectious (eg, fungal) skin reactions, more advanced 
ones with scarring alopecias including primary scar-
ring alopecias, such as LPP, alopecia mucinosa, follicu-
litis decalvans or secondary scarring alopecias such as 
morphea, cicatricial pemphigoid, neoplastic, traumatic 
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or infection- associated granulomatous scarring alope-
cias. In clinical settings, the diagnosis can be difficult and 
histopathological confirmation is usually required.4 33 34 
In this study, we performed gene expression analysis on 
plucked HFs from patients with CDLE and psoriasis, as 
well as healthy individuals. This pilot study showed that 
disease-specific signatures can be obtained from plucked 
HFs and this offers a promising, non-invasive, easy to 
perform approach with advantages over the use of skin 
biopsies. However, for diagnostic purposes it would be 
highly desirable to measure the identified signature mole-
cules on the protein levels as this would allow for a higher 
sample stability, lower costs and less labour and time-con-
suming analysis. Our results revealed that ISG are signifi-
cantly upregulated in lesional CDLE HFs and the pattern 
of differentially regulated genes resembles those found 
in previous reports on lesional full skin biopsies from 
patients with CDLE compared with healthy individuals 
or patients with psoriasis.8 35–37 Our finding of increased 
expression of the apoptosis-related genes, such as OAS2, 
OASL, XAF138–40 in lesional CDLE is also consistent with 
previously published reports using full skin biopsies.37 41 
Our analysis demonstrates a distinct molecular signature 
for lesional CDLE with strong upregulation of ISG, apop-
tosis, complement and MHC I related genes which are 
hallmarks of the immunopathology in CDLE.1 8 20 42–44 
CXCR3 ligands produced in response to epithelial IFNκ/
IFNλ15 27 45 attract CD8+ cytotoxic T cells to the bulge area 
of the HFs leading to irreversible damage to the stem cell 
niche residing in this area, thus resulting in atrophic scar-
ring.23 46–48 Within the normal bulge area, MHC class I and 
β2M are found downregulated and this stem cell niche 
is normally protected from inflammatory challenges, a 
phenomenon called ‘immune privilege (IP)’.22 23 49 In 
line with previous findings for scarring LPP,48 our data 
also point to IP collapse via increased expression of 
MHC class I (online supplementary table) and β2M in 
HF epithelium of lesional CDLE compared with non-le-
sional and healthy controls. Our microarray data show a 
slight tendency for downregulation of the key stem cell 
markers K15, CD200, Lhx2 and PHLDA1 residing within 
this area when comparing lesional CDLE with healthy/
non-lesional CDLE (data not shown).
Regarding psoriasis, which can present with florid scalp 
inflammation, the HF IP is maintained and scarring hair 
loss is not seen although ISG have been found in psori-
atic inflammation of the skin. This is in line with previous 
molecular analysis of scalp psoriasis highlighting it as an 
interfollicular disease.30 Supporting those findings, our 
analysis found low expression of inflammatory mole-
cules including ISGs in HFs from patients with psoriasis. 
This suggests that the HF may be actively protected from 
inflammatory attack. In the psoriasis samples, KDR expres-
sion was higher compared with lesional CDLE (table 1). 
KDR is one of the two VEGFRs. Angiogenesis is due to 
the action of vascular endothelial growth factor, which 
is a key molecule in psoriatic skin.50 Reduced angiogen-
esis observed in CDLE may be due to high expression 
of GBP-1,20 which is well known for its action on new 
vessel formation. CDLE is characterised by atrophy and 
insufficient tissue repair response and the marked down-
regulation of BMP2, which was among the most downreg-
ulated genes found, is interesting in this context. BMPs 
are signalling molecules belonging to the transforming 
growth factor (TGFβ) superfamily.51 BMPs are implicated 
in a variety of pathophysiological processes in the skin 
including wound healing.51 52 Thus, increased cellular 
senescence, reduced angiogenesis due to high expression 
of GBP-1,20 as well as cytotoxic attack of the HF stem cell 
compartments and the impact of BMP2 on TGFβ path-
ways are likely to contribute to atrophic scarring seen in 
patients with CDLE.53 Once the HF is lost, consequences 
for tissue repair may deteriorate. Plikus et al reported that 
during the wound healing process, only those dermal 
cells which were adjacent to the regenerated HFs differ-
entiated into lipid-laden newly formed adipocytes, but 
those in the hairless skin did not, suggesting that HFs are 
necessary to establish adipocyte precursors and normal 
wound repair.54 Similar to CDLE, LPP leads to permanent 
scarring14 and shares some molecular characteristics with 
CDLE,48 hence the differential diagnosis can be diffi-
cult.13 While LPP samples were not included in this pilot 
project, our qRT-PCR validation data showed a significant 
increase in C3 in lesional CDLE (figure 2), which is used 
together with immunoglobulin deposits at the basement 
membrane zone (dermoepidermal junction) to differ-
entiate between patients with CDLE and LPP using DIF 
in skin biopsies.11–13 Keratinocytes have been shown to 
synthesise C3 in response to cytokines, such as CCL2 and 
IFNɣ.55 56 Interestingly, CCL2 was among the most upreg-
ulated genes in the microarray analysis (online supple-
mentary data). Our results show only subtle differences 
between the non-lesional CDLE and healthy samples, 
suggesting non-lesional HFs of patients with CDLE are 
only mildly affected by the disease. Patients with CDLE 
recruited to this study followed measures of ultraviolet 
(UV) light protection. We have not yet analysed sun-ex-
posed HFs from patients with LE, which could well show 
subclinical inflammation.
In summary, this pilot project shows great potential 
regarding the diagnostic value of analysed plucked HFs. 
Once validated and optimised for protein detection, this 
could offer a significant advantage in clinical settings 
where the diagnosis of inflammatory lesions in HF-rich 
areas, such as the scalp, is often difficult and delayed due 
to the need of diagnostic biopsies and histopathological 
assessment. With the results obtained so far, we propose a 
diagnostic panel (figure 3), using plucked HFs followed 
by analysis of selected molecules, which should allow 
distinguishing CDLE from other pathologies. However, 
this requires validation in a prospective clinical study 
and comparison with standard dermatohistology diag-
nosis. Using this approach has the potential to save cost 
and avoid invasive biopsies, but would also offer signifi-
cant advantages for research into the pathophysiology of 
scarring alopecias by allowing repeated sampling in the 
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context of environmental challenges (eg, UV) or thera-
peutic interventions.
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